Insider Selling: Aura Biosciences (NASDAQ:AURA) Insider Sells $241,098.88 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 47,648 shares of Aura Biosciences stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $5.06, for a total transaction of $241,098.88. Following the transaction, the insider directly owned 409,815 shares of the company’s stock, valued at approximately $2,073,663.90. This represents a 10.42% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Los Pinos Elisabet De also recently made the following trade(s):

• On Tuesday, January 20th, Los Pinos Elisabet De sold 16,928 shares of Aura Biosciences stock. The stock was sold at an average price of $4.86, for a total transaction of $82,270.08.

Aura Biosciences Stock Performance

AURA opened at $5.36 on Friday. The stock has a market cap of $340.36 million, a price-to-earnings ratio of -2.76 and a beta of 0.46. The stock’s 50 day moving average price is $5.55 and its 200-day moving average price is $5.95. Aura Biosciences, Inc. has a one year low of $4.34 and a one year high of $7.80.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AURA. Evercore initiated coverage on Aura Biosciences in a research report on Tuesday, November 25th. They set an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a report on Monday, December 29th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.50.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its holdings in shares of Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock valued at $40,000 after purchasing an additional 2,104 shares in the last quarter. ProShare Advisors LLC purchased a new position in Aura Biosciences during the fourth quarter valued at approximately $59,000. Water Island Capital LLC bought a new position in Aura Biosciences in the third quarter worth approximately $64,000. 49 Wealth Management LLC bought a new position in Aura Biosciences in the third quarter worth approximately $66,000. Finally, Invesco Ltd. purchased a new stake in Aura Biosciences during the second quarter worth $76,000. Hedge funds and other institutional investors own 96.75% of the company’s stock.

About Aura Biosciences

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.